355 related articles for article (PubMed ID: 29378530)
1. Comparison of efficacy between anti-vascular endothelial growth factor (VEGF) and laser treatment in Type-1 and threshold retinopathy of prematurity (ROP).
Li Z; Zhang Y; Liao Y; Zeng R; Zeng P; Lan Y
BMC Ophthalmol; 2018 Jan; 18(1):19. PubMed ID: 29378530
[TBL] [Abstract][Full Text] [Related]
2. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity.
Sankar MJ; Sankar J; Chandra P
Cochrane Database Syst Rev; 2018 Jan; 1(1):CD009734. PubMed ID: 29308602
[TBL] [Abstract][Full Text] [Related]
3. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity.
Sankar MJ; Sankar J; Mehta M; Bhat V; Srinivasan R
Cochrane Database Syst Rev; 2016; 2():CD009734. PubMed ID: 26932750
[TBL] [Abstract][Full Text] [Related]
4. Comparison of different agents and doses of anti-vascular endothelial growth factors (aflibercept, bevacizumab, conbercept, ranibizumab) versus laser for retinopathy of prematurity: A network meta-analysis.
Ortiz-Seller A; Martorell P; Barranco H; Pascual-Camps I; Morcillo E; Ortiz JL
Surv Ophthalmol; 2024; 69(4):585-605. PubMed ID: 38432359
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Bevacizumab, Ranibizumab, and Laser Photocoagulation in the Treatment of Retinopathy of Prematurity in Turkey.
Gunay M; Sukgen EA; Celik G; Kocluk Y
Curr Eye Res; 2017 Mar; 42(3):462-469. PubMed ID: 27420302
[TBL] [Abstract][Full Text] [Related]
6. A Network Meta-Analysis of Retreatment Rates following Bevacizumab, Ranibizumab, Aflibercept, and Laser for Retinopathy of Prematurity.
Chang E; Josan AS; Purohit R; Patel CK; Xue K
Ophthalmology; 2022 Dec; 129(12):1389-1401. PubMed ID: 35842190
[TBL] [Abstract][Full Text] [Related]
7. The efficacy and ocular safety following aflibercept, conbercept, ranibizumab, bevacizumab, and laser for retinopathy of prematurity: a systematic review and meta-analysis.
Chen J; Hao Q; Zhang J; Du Y; Chen H; Cheng X
Ital J Pediatr; 2023 Oct; 49(1):136. PubMed ID: 37814332
[TBL] [Abstract][Full Text] [Related]
8. Anti-Vascular Endothelial Growth Factor Therapy for Primary Treatment of Type 1 Retinopathy of Prematurity: A Report by the American Academy of Ophthalmology.
VanderVeen DK; Melia M; Yang MB; Hutchinson AK; Wilson LB; Lambert SR
Ophthalmology; 2017 May; 124(5):619-633. PubMed ID: 28341474
[TBL] [Abstract][Full Text] [Related]
9. Characteristics of 'sawtooth shunt' following anti-vascular endothelial growth factor for aggressive posterior retinopathy of prematurity.
Padhi TR; Das T; Kaur P; Sutar S; Khalsa A; Modi R; Ali H; Pradhan L; Jalali S
Int Ophthalmol; 2020 Apr; 40(4):1007-1015. PubMed ID: 31925658
[TBL] [Abstract][Full Text] [Related]
10. Refractive Outcomes of 4-Year-old Children after Intravitreal Anti-vascular Endothelial Growth Factor versus Laser Photocoagulation for Retinopathy of Prematurity.
Kang HG; Kim TY; Han J; Han SH
Korean J Ophthalmol; 2019 Jun; 33(3):272-278. PubMed ID: 31179659
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of intravitreal bevacizumab for zone-II retinopathy of prematurity.
Karkhaneh R; Khodabande A; Riazi-Eafahani M; Roohipoor R; Ghassemi F; Imani M; Dastjani Farahani A; Ebrahimi Adib N; Torabi H
Acta Ophthalmol; 2016 Sep; 94(6):e417-20. PubMed ID: 27009449
[TBL] [Abstract][Full Text] [Related]
12. Reactivation of retinopathy of prematurity after ranibizumab treatment.
Wong RK; Hubschman S; Tsui I
Retina; 2015 Apr; 35(4):675-80. PubMed ID: 25768252
[TBL] [Abstract][Full Text] [Related]
13. The German ROP Registry: data from 90 infants treated for retinopathy of prematurity.
Walz JM; Bemme S; Pielen A; Aisenbrey S; Breuß H; Alex AF; Wagenfeld L; Schiedel S; Krohne TU; Stahl A;
Acta Ophthalmol; 2016 Dec; 94(8):e744-e752. PubMed ID: 27197876
[TBL] [Abstract][Full Text] [Related]
14. Antivascular endothelial growth factor in the treatment of retinopathy of prematurity.
Patel JR; Ranjan SS; Wasserman BN
Curr Opin Ophthalmol; 2016 Sep; 27(5):387-92. PubMed ID: 27206263
[TBL] [Abstract][Full Text] [Related]
15. Intravitreal anti-VEGF therapy as a treatment for retinopathy of prematurity: what we know after 7 years.
Klufas MA; Chan RV
J Pediatr Ophthalmol Strabismus; 2015; 52(2):77-84. PubMed ID: 25798707
[TBL] [Abstract][Full Text] [Related]
16. Study protocol for prognosis and treatment strategy of peripheral persistent avascular retina after intravitreal anti-VEGF therapy in retinopathy of prematurity.
Yu Y; Wang J; Chen F; Chen W; Jiang N; Xiang D
Trials; 2020 Jun; 21(1):493. PubMed ID: 32513245
[TBL] [Abstract][Full Text] [Related]
17. A Dosing Study of Bevacizumab for Retinopathy of Prematurity: Late Recurrences and Additional Treatments.
Wallace DK; Dean TW; Hartnett ME; Kong L; Smith LE; Hubbard GB; McGregor ML; Jordan CO; Mantagos IS; Bell EF; Kraker RT;
Ophthalmology; 2018 Dec; 125(12):1961-1966. PubMed ID: 29887334
[TBL] [Abstract][Full Text] [Related]
18. Chronic Vascular Arrest as a Predictor of Bevacizumab Treatment Failure in Retinopathy of Prematurity.
Toy BC; Schachar IH; Tan GS; Moshfeghi DM
Ophthalmology; 2016 Oct; 123(10):2166-75. PubMed ID: 27506484
[TBL] [Abstract][Full Text] [Related]
19. [Retinopathy of prematurity - therapy. Part 2].
Prepiaková Z; Tomčíková D; Kostolná B; Gerinec A
Cesk Slov Oftalmol; 2014 Apr; 70(2):50-4. PubMed ID: 25030312
[TBL] [Abstract][Full Text] [Related]
20. Refractive outcomes after intravitreal injection of antivascular endothelial growth factor versus laser photocoagulation for retinopathy of prematurity: a meta-analysis.
Kong Q; Ming WK; Mi XS
BMJ Open; 2021 Feb; 11(2):e042384. PubMed ID: 33568373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
